U.S. Markets open in 48 mins.

Bayer Aktiengesellschaft (BAYN.DE)


XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
121.90-0.25 (-0.20%)
As of 2:25PM CEST. Market open.
Full screen
Previous Close122.15
Open122.10
Bid121.90 x 28400
Ask121.95 x 2100
Day's Range120.90 - 122.25
52 Week Range86.03 - 123.90
Volume509,569
Avg. Volume1,833,579
Market Cap100.78B
BetaN/A
PE Ratio (TTM)20.16
EPS (TTM)6.05
Earnings DateJul 27, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est118.08
  • Reuters6 days ago

    U.S. Supreme Court ruling threatens massive talc litigation against J&J

    Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer. New Jersey-based J&J has been battling a series of lawsuits over its talc-based products, including Johnson's Baby Powder, brought by around 5,950 women and their families. The company denies any link between talc and cancer.

  • Reuters7 days ago

    Novartis eye drug works at less frequent dosing than rival's

    The drug, whose generic name is brolucizumab, aims to treat neovascular age-related macular degeneration (nAMD), the leading cause of severe vision loss and blindness in people over the age of 65 in North America, Europe, Australia and Asia. Head-to-head late-stage trials showed RTH258 worked as well as Regeneron's Eylea, developed with Bayer. This was achieved with over half the patients dosed every 12 weeks compared to every eight weeks with Eylea.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of BAYN.DE earnings conference call or presentation 26-Oct-16 12:00pm GMT

    Q3 2016 Bayer AG Earnings Call